Puig CEO Unveils Plan To Become An €8 Billion-plus Beauty Company By 2032
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

Puig says it aims to exceed €8 billion in annual net revenues by 2032 and become one of the top four premium beauty companies. Its plan relies primarily on organic growth across four areas, with a proposed Isdin acquisition adding to its dermocosmetics ambitions if the deal receives approval.

Puig CEO José Manuel Albesa presented a six-year growth plan on October 28 in Madrid, with the Spanish beauty group targeting more than €8 billion in annual net revenues by 2032. Called Vision 2032, the strategy also sets goals for a top-four position in premium beauty, a top-two position in fragrance and an adjusted EBITDA margin above 22.5%.

Before you orderOffer from Amazon

Get beauty and skincare favorites delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

Puig said it expects to pursue the revenue target primarily through organic growth, scaling its portfolio across prestige fragrances, niche fragrances, dermocosmetics and Charlotte Tilbury. The company also said selective acquisitions could complement that growth by adding brands, capabilities or access to attractive categories and markets. The targets are company ambitions, not guaranteed outcomes.

In prestige fragrance, Puig plans to build its feminine perfume business, which it says represents about 45% of its own prestige fragrance sales, compared with approximately 65% of the global prestige fragrance market. It intends to develop Carolina Herrera across fragrance and make-up, while expanding the fragrance portfolios of Rabanne and Jean Paul Gaultier. For niche fragrance brands Byredo and Penhaligon’s, the plan calls for productivity gains and selective expansion, particularly in the United States and Asia, while retaining exclusivity and profitability.

Puig aims to grow Charlotte Tilbury’s business by 1.5 times by 2032, through make-up, skin care, fragrance innovation planned for 2028 and selective distribution expansion. The brand, acquired in 2020, has more than tripled in size since then, according to the report. In dermocosmetics, Puig targets doubling sales at Uriage and has agreed to acquire full ownership of Isdin from Corporación Químico-Farmacéutica Esteve. Isdin recorded approximately €650 million in 2025 revenue; the proposed transaction is expected to close in the first quarter of 2027, subject to regulatory approvals.

At a glance
announcementWhen: Announced October 28, 2026; Isdin trans…
The developmentAt its 2026 Capital Markets Day in Madrid, Puig CEO José Manuel Albesa presented Vision 2032, a plan targeting more than €8 billion in annual net revenues by 2032.

Four Businesses Carry the Growth Plan

The targets would require Puig to increase annual net revenues from more than €5 billion in 2025 to above €8 billion by 2032, while also improving profitability. The company says it has more than tripled revenue over the past five years and gained share in fragrance, make-up and skin care. Its new plan tests whether that momentum can continue across several distinct businesses and regions.

The proposed Isdin deal is relevant to that mix because it could give Puig a larger base in dermocosmetics, alongside Uriage and Apivita. Puig estimates those brands together would have more than €1 billion in pro forma net revenues after completion. That figure is conditional on the transaction closing and describes a combined platform, not a current standalone result.

Puig also plans a more integrated operating model for global brands, markets and functions, while saying it will preserve creative autonomy. The company says its regional approach will reinforce EMEA, Latin America and travel retail, while pursuing opportunities in North America and Asia-Pacific. Execution across these priorities will determine whether its growth and margin goals are attainable.

Products Worth Considering

Therabody Theragun PRO Plus 6-in-1 Deep Tissue Massage Gun, Black

Therabody Theragun PRO Plus 6-in-1 Deep Tissue Massage Gun, Black

Therabody Theragun Prime Plus Heated Deep Tissue Massage Gun, Black

Therabody Theragun Prime Plus Heated Deep Tissue Massage Gun, Black

As an affiliate, we earn on qualifying purchases.

The Business Behind Vision 2032

Puig presented the plan at its Capital Markets Day 2026, an investor-focused event outlining the company’s priorities for its next growth phase. The group is a multi-brand premium beauty company with businesses in fragrances, make-up and skin care. It described its record over the past five years as faster growth than the premium beauty market, alongside share gains across those categories.

The company cited its travel-retail performance as one example of expansion: it said Puig moved from the sixth-largest to the third-largest fragrance player in that channel since 2021, increasing share from 9.6% to 13.0%. That past performance provides context for the new targets, but does not establish that future growth will match the same pace.

Executive Chairman Marc Puig said the group’s plan is rooted in organic growth from its existing portfolio, with acquisitions used selectively. Vision 2032 therefore combines expansion of established brands with geographic growth and the proposed addition of Isdin, rather than relying on a single product or market.

““The plan is grounded in organic growth from the existing portfolio, complemented by selective acquisitions that add distinctive brands, capabilities or exposure to attractive categories and markets.””

— Marc Puig, Puig executive chairman

Targets Depend on Execution and Approval

Puig has not provided, in the cited report, a year-by-year revenue path to more than €8 billion or a detailed breakdown of how much each business is expected to contribute. The company’s targets are forward-looking ambitions; the report does not establish that they will be achieved or specify the assumptions behind the adjusted EBITDA margin goal.

The Isdin transaction remains conditional. Puig expects it to close in the first quarter of 2027, but regulatory approval is still required. The cited material does not give the purchase price or further terms of the deal. It is also unclear how the planned operating model changes will be implemented in practice or how much they are expected to contribute to growth and margins.

Isdin Deal and Brand Expansion

The next stated milestone is the proposed completion of the Isdin transaction in the first quarter of 2027, subject to regulatory approvals. Puig’s progress can then be measured against its stated portfolio plans: expanding Carolina Herrera and other prestige fragrance brands, growing Byredo and Penhaligon’s selectively, and extending Charlotte Tilbury across categories, including fragrance innovation planned for 2028.

For investors and the beauty industry, the key indicators will be Puig’s revenue and margin performance, the pace of organic growth across its four focus areas, and whether the company can expand internationally without weakening brand positioning. The company has announced the goals and strategic priorities; further detail on annual milestones and results will depend on future disclosures.

Key Questions

What is Puig targeting by 2032?

Puig is targeting more than €8 billion in annual net revenues, a top-four position in premium beauty, a top-two position in fragrance and an adjusted EBITDA margin above 22.5%.

How does Puig plan to grow?

The company says growth will come primarily from organic expansion across prestige fragrances, niche fragrances, dermocosmetics and Charlotte Tilbury, with selective acquisitions as a possible complement.

What is the status of the Isdin deal?

Puig has agreed to acquire full ownership of Isdin from Corporación Químico-Farmacéutica Esteve. Completion is expected in the first quarter of 2027, subject to regulatory approvals.

How much revenue did Isdin report?

Isdin generated approximately €650 million in revenue in 2025, according to the source report. Puig says Isdin, Uriage and Apivita would form a dermocosmetics platform with more than €1 billion in pro forma net revenues after the transaction closes.

Source: cosmeticsbusiness.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

DedCool’s Newest Scent “Mocha Magic” Is Here

DedCool has introduced its latest fragrance, ‘Mocha Magic,’ expanding its scent lineup amid rising consumer interest and trend signals in niche perfumery.

Tate McRae Celebrates Her Fragrance Launch With A Saint Laurent Slip And A Perfectly On-Theme Necklace

Tate McRae marked the launch of Tate 01 at a New York event, wearing a Saint Laurent silver slip dress and a necklace echoing the perfume bottle.

Kromboost

Search interest in Kromboost spikes sharply, though details remain unconfirmed. Experts suggest growing curiosity in the product’s potential benefits.

The Coach Tabby Bag Is Red-Carpet Worthy, According To The CFDA Fashion Awards

Elle Fanning, Lola Tung and PinkPantheress carried distinct Coach Tabby bags at the 2026 CFDA Fashion Awards in New York.